Login / Signup
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC.
Yingqi Xu
Yidan Zhang
Huiping Qiang
Hua Zhong
Jianlin Xu
Runbo Zhong
Published in:
Lung cancer (Amsterdam, Netherlands) (2024)
Patients with advanced ROS1-rearranged NSCLC were found to benefit from first-line crizotinib treatment, irrespective of baseline PD-L1 expression.
Keyphrases
</>
advanced non small cell lung cancer
small cell lung cancer
cell death
dna damage
epidermal growth factor receptor
reactive oxygen species
brain metastases
oxidative stress
tyrosine kinase
replacement therapy